NCT03364257 (IDENTIFY) is a clinical trial of iDTECT Blood in Febrile Neutropenia, sponsored by Pathoquest.

Who is sponsoring NCT03364257?

NCT03364257 is sponsored by Pathoquest.

What drugs are being tested in NCT03364257?

Interventions in NCT03364257: iDTECT Blood.

What condition does NCT03364257 study?

NCT03364257 studies Febrile Neutropenia, Acute Leukemia, Stem Cell Transplantation, Infection.

Is NCT03364257 still recruiting?

NCT03364257 is currently status unknown. Last updated 21 March 2019.

Last reviewed 2019-03-21 · How we verify

NCT03364257: IDENTIFY

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

iDTECT Blood Performance for the Identification of Viral or Bacterial Pathogens in Febrile Neutropenic Patients

Status unknown Last updated 21 March 2019

What this trial tests

trial testing iDTECT Blood in Febrile Neutropenia in 97 participants. Status unknown.

Timeline

18 May 2018

Primary endpoint
30 April 2019

31 May 2019

Quick facts

Lead sponsor	Pathoquest
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	97
Start date	18 May 2018
Primary completion	30 April 2019
Estimated completion	31 May 2019
Sites	5 locations across France

Drugs / interventions tested

iDTECT Blood

Conditions studied

Febrile Neutropenia — all drugs for Febrile Neutropenia →
Acute Leukemia — all drugs for Acute Leukemia →
Stem Cell Transplantation — all drugs for Stem Cell Transplantation →
Infection — all drugs for Infection →

Sponsor

Pathoquest

Who can join

5 and older, any sex, with Febrile Neutropenia or Acute Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective, multicentre French observational study assessing the performance and medico-economic utility of iDTECT Blood versus conventional microbiologic diagnosis in patients with febrile neutropenia

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Febrile Neutropenia

Currently open trials in the same condition.

NCT07204522 — Efficacy of Empirical Anti-Infective Therapy in Neutropenic Febrile Patients. · recruiting
NCT05815628 — Next-Generation-Sequencing Approach to Neutropenic Sepsis · recruiting
NCT06787326 — Effect of the BioFire FilmArray (BCID2) for the Rapid Detection of Bloodstream Infection in Haematologic Patients With F · active not recruiting
NCT05786495 — Short Antibiotic Treatment in High Risk Febrile Neutropenia · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03364257 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pathoquest
Last refreshed: 21 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03364257.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing